Clinical Guidelines for Interstitial Lung Disease Multidisciplinary Review

Abstract

Interstitial lung disease (ILD) encompasses a heterogeneous group of pulmonary disorders characterized by varying degrees of inflammation, fibrosis, and impaired gas exchange. The complexity and diversity of ILD subtypes necessitate a multidisciplinary approach to diagnosis and management. This review synthesizes current guidelines and recent evidence, emphasizing diagnostic strategies, risk stratification, and evolving therapeutic modalities. Practical insights for clinicians are provided, with a focus on optimizing patient outcomes through multidisciplinary collaboration.

Introduction

Interstitial lung disease represents a spectrum of over 200 pulmonary disorders, unified by diffuse parenchymal involvement. Accurate diagnosis and appropriate management are challenging due to overlapping clinical and radiological features. Multidisciplinary team (MDT) review has emerged as the cornerstone for ILD evaluation, integrating pulmonology, radiology, pathology, and rheumatology expertise. This review aims to provide an up-to-date synthesis of clinical guidelines, with emphasis on evidence-based, mechanism-driven management strategies and multidisciplinary collaboration.

Epidemiology / Disease Burden

The global prevalence of ILD varies geographically, with idiopathic pulmonary fibrosis (IPF) being the most studied subtype. In Europe and North America, IPF prevalence ranges from 14 to 63 per 100,000 population. Non-IPF ILDs, such as connective tissue disease-associated ILD (CTD-ILD) and hypersensitivity pneumonitis, contribute significantly to the burden, particularly in populations with high autoimmune disease prevalence. ILD is associated with substantial morbidity, reduced quality of life, and high healthcare utilization. Despite advances in therapy, mortality remains high, especially in fibrotic phenotypes.

Pathophysiology

ILD pathogenesis involves a complex interplay of genetic susceptibility, environmental exposures, immune dysregulation, and aberrant wound healing. In IPF, repetitive alveolar epithelial injury leads to dysregulated fibroblast proliferation and excessive extracellular matrix deposition, resulting in progressive fibrosis and impaired gas exchange. Inflammatory pathways dominate in non-specific interstitial pneumonia (NSIP) and CTD-ILD, where immune-mediated alveolitis precedes fibrosis. Understanding these mechanisms underpins targeted therapy development and informs clinical management.

Risk Factors

Established risk factors for ILD include older age, male sex (notably in IPF), cigarette smoking, occupational and environmental exposures (e.g., asbestos, silicates, organic dusts), and genetic predisposition (e.g., mutations in surfactant protein genes, telomerase complex genes). In CTD-ILD, underlying autoimmune conditions such as rheumatoid arthritis and systemic sclerosis are significant contributors. Drug-induced ILD, notably from amiodarone, methotrexate, and checkpoint inhibitors, is increasingly recognized. A detailed exposure and medication history is vital in risk assessment.

Clinical Features

Common presenting symptoms of ILD are insidious and non-specific, including progressive exertional dyspnea, non-productive cough, and fatigue. Physical examination may reveal bibasilar inspiratory crackles and digital clubbing, particularly in advanced stages. Extrapulmonary manifestations are prominent in CTD-ILD, such as arthralgias, Raynaud's phenomenon, and skin changes. Acute exacerbations, characterized by rapid deterioration in respiratory function and new radiological infiltrates, are associated with high mortality, underscoring the need for vigilant monitoring.

Diagnosis

Current guidelines advocate for a structured, MDT-based diagnostic approach. High-resolution computed tomography (HRCT) remains the gold standard for radiological assessment, distinguishing between UIP (usual interstitial pneumonia) and non-UIP patterns. Serological testing for autoimmune markers, pulmonary function testing (PFTs), and bronchoalveolar lavage (BAL) contribute to subtype differentiation. Surgical lung biopsy, while informative, is reserved for cases with indeterminate HRCT findings due to procedural risks. MDT discussion integrates clinical, radiological, and pathological data to achieve consensus diagnosis, improving diagnostic accuracy and prognostication.

Treatment & Management

Management strategies are tailored to ILD subtype, severity, and progression rate. Antifibrotic agents, including nintedanib and pirfenidone, are standard of care in IPF and show efficacy in progressive fibrosing non-IPF ILD. Immunosuppressive therapy (e.g., mycophenolate mofetil, azathioprine) is indicated in inflammatory ILDs, such as CTD-ILD and NSIP. Supportive care, encompassing supplemental oxygen, pulmonary rehabilitation, and vaccination, is essential across all ILD forms. Early referral for lung transplantation assessment is warranted in advanced disease. Regular MDT review ensures dynamic, individualized care plans.

Recent Advances / Emerging Therapies

Recent trials have expanded therapeutic options for ILD, particularly in progressive fibrosing phenotypes. The INBUILD trial demonstrated nintedanib's benefit in non-IPF fibrosing ILDs, prompting guideline revisions. Biologic agents targeting specific immune pathways (e.g., rituximab, tocilizumab) are under investigation in refractory CTD-ILD. Molecular diagnostics and genomic profiling may enable personalized therapy in the near future. Emerging evidence supports the role of antifibrotics in combination with immunomodulators, although optimal regimens remain under study.

Guideline Recommendations

International guidelines from ATS/ERS/JRS/ALAT emphasize the primacy of MDT review in ILD diagnosis and management. HRCT is endorsed as first-line imaging, with lung biopsy reserved for selected cases. Antifibrotic therapy is recommended for IPF and progressive fibrosing ILDs. Immunosuppression is advocated for inflammatory subtypes, guided by disease activity and comorbidity profile. Regular monitoring with PFTs and clinical assessment is advised. Vaccination against influenza and pneumococcus is universally recommended. Palliative care integration is encouraged for symptom management and end-of-life planning.

Conclusion

The management of interstitial lung disease is inherently complex, necessitating a collaborative multidisciplinary approach. Advances in diagnostic modalities, therapeutic agents, and personalized care models have improved outcomes, yet significant challenges remain. Ongoing research, guideline refinement, and MDT engagement are pivotal to optimizing care for this diverse patient population. Clinicians must remain abreast of evolving evidence and embrace multidisciplinary strategies to ensure the highest standard of care in ILD.